Disease Does Not Begin the Day Your Bloodwork Turns Red

By Atlas Lifespan
A heart attack can be the first symptom of atherosclerosis. Type 2 diabetes can appear only after years of insulin
resistance and progressive beta-cell strain. A “normal” laboratory report does not always mean the underlying
biology is low risk.
Routine bloodwork remains essential, but reports use diagnostic thresholds while chronic disease develops along a
continuum. Longevity medicine asks: What is changing before organ damage or a clinical event makes the risk
obvious?

Normal is a statistical category, not a physiologic conclusion

Reference ranges describe populations. They do not measure the direction or speed of change within one person.
A fasting glucose of 96 mg/dL may look unremarkable. If it rose from 78 while triglycerides, waist circumference, and
blood pressure increased, the pattern may reflect deteriorating metabolic health. Conversely, an isolated abnormality
after illness or dehydration may be insignificant.
A physician asks whether the result is reproducible, how it changed, and whether clarification would alter
management.

Glucose may remain normal while insulin resistance advances

Skeletal muscle, liver, and adipose tissue can become less responsive to insulin before fasting glucose or A1c
reaches a diagnostic threshold. Pancreatic beta cells compensate by producing more insulin, preserving glucose at
the cost of increasing metabolic strain.
Insulin resistance is linked to high triglycerides, hypertension, visceral adiposity, metabolic liver disease, and
endothelial dysfunction. A1c may conceal post-meal excursions and can be distorted by anemia, kidney failure,
altered red-cell turnover, pregnancy, or transfusion.
Advanced testing is most useful when phenotype and routine results disagree, or when the answer would change management.

ApoB and Lp(a) reveal risks that LDL cholesterol can miss

LDL cholesterol estimates how much cholesterol is carried inside LDL particles. Apolipoprotein B estimates the
number of atherogenic particles capable of entering the arterial wall. Two patients can have the same LDL
cholesterol but different particle numbers and therefore different opportunities for plaque formation.
In CARDIA, 2,794 young adults were followed for 25 years. Compared with the lowest ApoB group, the middle and
highest groups had adjusted odds ratios of 1.53 and 2.28 for later coronary calcium. In MESA, higher ApoB was
associated with CAC prevalence, development, and progression. Discordantly high ApoB relative to LDL cholesterol
was also associated with CAC progression, although its added predictive value was modest.
Lp(a) adds a different signal. It is inherited and carries atherogenic, pro-inflammatory oxidized phospholipids. The
2026 ACC and AHA guideline recommends measuring it at least once in adulthood. At 125 nmol/L, long-term heartattack or stroke risk is about 1.4-fold higher. At 250 nmol/L, it is at least doubled.

Calcium scoring shows whether coronary plaque is already present

ApoB and Lp(a) estimate exposure to plaque-forming biology. Coronary artery calcium, or CAC, measures the
calcified plaque burden that has accumulated in the coronary arteries. These tests are related, but they are not
interchangeable.
In MESA, 6,814 adults without known cardiovascular disease were followed for 11.1 years. Ten-year ASCVD event
rates ranged from 1.3 to 5.6 percent with CAC 0 and from 13.1 to 25.6 percent with CAC above 300. Every subgroup
with CAC of at least 100 exceeded 7.5 percent 10-year risk. Each CAC doubling increased relative risk by 14
percent after adjustment.
The combination is especially useful. In 4,512 MESA participants, elevated Lp(a) plus CAC of at least 100 produced
a 4.71-fold adjusted hazard of an ASCVD event and a 10-year incidence of 23.2 percent compared with neither
finding. Elevated Lp(a) with CAC 0 carried much lower 10-year risk, but CAC 0 does not erase lifetime risk or
exclude noncalcified plaque.
CAC can reclassify an uncertain prevention decision, while ApoB and Lp(a) define ongoing exposure and lifetime
risk. Together they may change lipid lowering, blood-pressure control, metabolic treatment, and follow-up. CAC is not for every patient or for evaluating acute chest pain.

The expertise is in integration, not test volume

The value of longevity medicine is connecting history, laboratory trajectories, body composition, ApoB, Lp(a), and
selective imaging into one defensible risk model.
The goal is not to turn a healthy person into a patient. It is to find silent disease or a dangerous trajectory while
prevention still has leverage.
Ready for personalized care? Book a discovery call with Atlas Lifespan

Clinical references

1. Wilkins JT, et al. ApoB discordance and coronary calcium in CARDIA. J Am Coll Cardiol. 2016. https://pubmed.ncbi.nlm.nih.gov/26791067/
2. Cao J, et al. ApoB discordance and CAC in MESA. J Clin Lipidol. 2020. https://pubmed.ncbi.nlm.nih.gov/31882375/
3. Budoff MJ, et al. Ten-year association of CAC with ASCVD events in MESA. Eur Heart J. 2018. https://pubmed.ncbi.nlm.nih.gov/29688297/
4. Mehta A, et al. Independent and joint associations of Lp(a) and CAC with ASCVD. J Am Coll Cardiol. 2022.https://pubmed.ncbi.nlm.nih.gov/35210030/
5. Blumenthal RS, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. https://pubmed.ncbi.nlm.nih.gov/41824590/